ROCKWELL MEDICAL, INC. 8-K

What Happened

• On May 8, 2026, Rockwell Medical, Inc. announced it received a notice from Nasdaq that its common stock failed to meet the minimum closing bid price requirement of $1.00 under Nasdaq Listing Rule 5550(a)(2).
• Nasdaq determined the deficiency existed based on the closing bid for the 30 consecutive business days prior to the notice. The notice does not immediately affect the listing — the company has until November 4, 2026 (a 180-calendar-day compliance period) to regain compliance.

Key Details

• Notice date: May 8, 2026. Compliance deadline: November 4, 2026 (180 days).
• Requirement to regain compliance: closing bid price ≥ $1.00 for at least 10 consecutive business days during the cure period.
• During the cure period the company’s common stock will remain listed and tradable on The Nasdaq Capital Market.
• Rockwell included a proposal in its 2026 Annual Meeting Proxy to implement a reverse stock split; if approved and implemented, the company believes this could restore compliance (no assurance provided).

Why It Matters

• For investors, this is a material risk signal: if Rockwell does not meet Nasdaq’s price requirement and cannot obtain relief, it could face delisting, which would reduce liquidity and may limit trading access.
• The 180-day cure period gives the company time to regain compliance (including via a potential reverse stock split), but there is no guarantee of success; trading continues for now.
• Monitor upcoming proxy vote results (reverse split proposal) and share-price performance through the November 4, 2026 deadline for developments that affect listing status.